Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Classical reporting system

Contexte Official surveillance system relies on official laws. The Lebanese Law related to communicable diseases issued on the 31st December 1957 requests from physicians and healthcare facilities to report to the MOPH selected communicable diseases.
On the other hand, the MOPH issues continuously decisions, circulars, and memos that specifies technical aspects of the national surveillance system (case definitions, forms…).
Objectives - Measure disease burden and describe the characteristics. This includes: a) Measure incidence, prevalence, and mortality rates; b) Describe event/disease by time, place and person; c) Monitor trends; d) Identify high risk populations or areas; e) Identify risk factors; f) Evaluate specific diseases control programs.
- Detect alerts and outbreaks. The detection of an outbreak gives an opportunity to investigate, find etiologies and implement corrective measures, thus aiming to reduce cases and prevent later outbreaks. Early warning and response system refers to the outbreak detection at early stages; when timely corrective measures can prevent additional new cases and stop the natural evolution of the outbreak.
Target diseases and syndromes 40 diseases and syndromes are targetted by the classical surveillance system. The diseases are displayed in 2 groups: immediate notification and weekly notification:
- The immediate notifiable diseases and syndromes are: Acute Flaccid Paralysis, Anthrax, Cholera, Diphtheria, Food Poisoning, Hemorrhagic Fever, Influenza novel viruses, Invasive Coranaviruses, Measles, Meningitis, Meningococcal infection, Mumps, Pertussis, Plague, Rabies, Rubella and Congenital Rubella Syndrome, Smallpox, Tetanus including Tetanus Neonatorum, and Unusual Event
- The weekly notifiable diseases and syndromes are: Bilharziasis, Brucellosis, Creutzfeldt-Jakob Disease (Transmissible Spongiform Encephalopathy), Gonococcal Infection,Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Human Immunodeficiency Virus, Human T-cell Lymphotropic Virus 1, Hydatid Disease, Intestinal Infections, Legionellosis, Leishmaniasis, Leprosy, Malaria, Syphilis, Tuberculosis, Typhoid Fever and Typhus.  
Data Sources All Physicians and Healthcare facilities
Guidelines - Communicable diseases surveillance guideline: Ar, En
- Communicable diseases surveillance standard operating procedures - part 1 (immediately notifiable diseases): En
- Communicable diseases surveillance standard operating procedures - part 2 (weekly notifiable diseases): En
Case definitions Refer to webpages "Notifiable Diseases"
Form Reporting form
Results Refer to webpage "Surveillance data"
    ...
    8
    ...
ATC Name B/G Ingredients Dosage Form Price
N02BF02 GABRIKA 25 G Pregabalin - 25mg 25mg Capsule 560,062 L.L
A08AB01 ELIZA 120 G Orlistat - 120mg 120mg Capsule 1,167,223 L.L
N02BF02 GABRIKA 25 G Pregabalin - 25mg 25mg Capsule 341,720 L.L
A08AB01 ELIZASLIM 120 G Orlistat - 120mg 120mg Capsule 1,167,223 L.L
N02BF02 NEUREXAL G Pregabalin - 25mg 25mg Capsule 321,754 L.L
A08AB01 LESSFAT G Orlistat - 120mg 120mg Capsule 391,634 L.L
N02BF02 PLENICA G Pregabalin - 25mg 25mg Capsule 697,454 L.L
A08AB01 ONLEFIT G Orlistat - 120mg 120mg Capsule 1,537,356 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 1mcg 1mcg Capsule 3,735,882 L.L
N02BF02 PMS-PREGABALIN G Pregabalin - 25mg 25mg Capsule 770,022 L.L
A08AB01 ORLISTAT-SIGMA G Orlistat - 120mg 120mg Capsule 847,965 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.25mcg 0.25mcg Capsule 1,138,235 L.L
B02BX01 DICYNONE B Etamsylate - 500mg 500mg Capsule 1,311,590 L.L
J01FF01 DALACIN-C B Clindamycin HCl - 150mg 150mg Capsule 287,582 L.L
A08AB01 ORLY SLIM G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.5mcg 0.5mcg Capsule 943,377 L.L
J01FF01 DALACIN-C B Clindamycin HCl - 300mg 300mg Capsule 478,408 L.L
M01AB01 INDOMEL G Indometacin - 25mg 25mg Capsule 170,220 L.L
A02BC05 ESOCAP-UBSA G Esomeprazole - 20mg 20mg Capsule 511,940 L.L
A08AB01 UNI-CAL G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.5mcg 0.5mcg Capsule 942,034 L.L
J01FF01 DANALLI G Clindamycin HCl - 300mg 300mg Capsule 267,425 L.L
A08AB01 LESSFAT G Orlistat - 60mg 60mg Capsule 1,039,238 L.L
A09AA02 CREON 10,000 B Pancreatin protease - 600FIP-U, Pancreatin amylase - 8,000FIP-U, Pancreatin lipase - 10,000FIP-U Capsule 1,835,689 L.L
A11CC05 ALTO D 10.000 G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
A09AA02 CREON 25,000 B Pancreatin protease - 1000FIP-U, Pancreatin amylase - 18000FIP-U, Pancreatin lipase - 25000FIP-U Capsule 4,598,629 L.L
A11CC05 ALTUM-D3 G Vitamin D3 - 10,000IU 10,000IU Capsule 561,342 L.L
A11CC05 BENTA D 10.000 G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
A11CC05 D-VITAL G Vitamin D3 - 10,000IU 10,000IU Capsule 561,342 L.L
A02BC05 PROTREX G Esomeprazole - 20mg 20mg Capsule 511,940 L.L
    ...
    8
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026